Acenocoumarol/fenprocoumon + Vemurafenib MFB 1190

Protrombinetijd = PT

Onderbouwend	Stof	Effect	Code
--			

Overig	Stof	Effect
SPC Marcoumar, acenocoumarol	acenocoumarol, fenprocoumon + nibben	noemt vemurafenib niet
SPC Zelboraf	acenocoumarol, fenprocoumon + nibben	noemt warfarine, zie aldaar.
ClinicalTrials.gov: http://clinicaltrials.gov/ct2/show/NCT01849666?term=vemurafenib&rank=28: geraadpleegd november 2013	fenprocoumon + vemurafenib	studie NCT01849666. A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy This open-label, multicenter, parallel study will evaluate the effect of multiple doses of vemurafenib on the pharmacokinetics of a single dose of phenprocoumon in patients with BRAFV600 mutation-positive metastatic malignancies. Patients will be randomized to receive either treatment A: a single oral dose of phenprocoumon 6 mg on Day 1 (Eligible patients will have the option to continue treatment with vemurafenib as part of an extension study (NCT01739764).), or treatment B: vemurafenib 960 mg orally twice daily on Days 1-29 plus a single oral dose of phenprocoumon 6 mg on Day 22 (with the option to receive vemurafenib in the extension study after completion of pharmacokinetic assessments). No publications provided

Opmerkingen

PubMed: geen informatie

Stockley, Hansten: geen informatie.

Risicofactoren	
Mitigerende factoren	

	Interactie	Actie	Datum
Beslissing WG OncoIA	Ja	Nee	8 januari 2014

Ter informatie: Warfarine + vemurafenib

Onderbouwend	Stof	Effect	Code
SPC Zelboraf + EPAR	warfarine + vemurafenib	toename AUC warfarine van 14964 naar 17804 ng*hr/ml (+20%) Regime: vemurafenib 960 mg 2dd gedurende 15 dagen (steady state), warfarine 1-malig	(2A)